T cell receptor specific for MAGE-A3–HLA complex (MAGE-A3 TCR)

T cell receptors (TCRs) specific for MAGE-A3–HLA complexes are engineered or naturally occurring receptors designed to recognize the Melanoma-associated antigen 3 (MAGE-A3) when presented by specific Human Leukocyte Antigen (HLA) molecules. MAGE-A3 is a cancer-testis antigen that is highly expressed in various malignancies, such as melanoma and non-small cell lung cancer, but is absent from normal adult tissues except for the testes, making it an ideal target for immunotherapy. Therapeutic strategies involving these TCRs typically utilize TCR-engineered T cell (TCR-T) therapy, where a patient's T cells are modified to express a high-affinity TCR targeting MAGE-A3. Upon infusion, these T cells recognize MAGE-A3-positive tumor cells, leading to targeted cytotoxicity and tumor regression. However, the development of MAGE-A3-specific TCRs has faced significant safety challenges, including lethal off-target toxicities. Specifically, affinity-enhanced TCRs have shown cross-reactivity with the cardiac protein titin and the brain-expressed MAGE-A12, leading to fatal cardiotoxicity and neurotoxicity, respectively. Current research focuses on identifying more selective TCRs, such as those restricted by MHC class II (HLA-DPB1*04:01), to improve the safety profile of these therapies.

Other names

MAGE-A3-specific T cell receptorAnti-MAGE-A3 TCRMAGE-A3/A12 TCRHLA-A*01-restricted MAGE-A3 TCRHLA-A*02-restricted MAGE-A3 TCRHLA-DPB1*04:01-restricted MAGE-A3 TCR

TCR-T cells express the engineered TCR, which binds to MAGE-A3 peptides presented by HLA molecules on the surface of tumor cells, initiating T cell activation, cytokine release, and direct lysis of the cancer cells.